Intravitreal triamcinolone will, more often than not, lead to the development of cataracts in eyes with diabetic macular oedema (DME), according to the results of a study published in the March 17, 2006 issue of Eye.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.